Johnson & Johnson On ‘Single-Dose’ COVID-19 Vaccine Data
Johnson & Johnson’s 2021 profit forecast goes way higher than “Wall Street estimates”.
Johnson & Johnson’s 2021 profit forecast goes way higher than “Wall Street estimates”.
The “UK Medicines and Healthcare products Regulatory Agency” gave its approval for Oxford/AstraZenca vaccine whereby vindicating the step towards essential “mass immunisations” across the globe.
The EU has a population of nearly 450 million, therefore mass vaccination across the continent would be a “crucial step” in the battle to end the pandemic.
Regulators are best placed to decide the efficacy of the vaccine with data which aren’t available in public domain.
Concerns related to vaccine distribution have brought back the pandemic situation under focus whereby highlighting some of the grim realities of the world.
Has the winning year for ‘corporate stay-at-homes’ come to an end?
If reports are to be believed, positive news has come about Oxford University’s COVID-19 vaccine.
Covaxin has received clearance for human trail from drug regulatory authorities of India.